Mendelspod was founded in 2011 by Theral Timpson and Ayanna Monteverdi to advance life science research, connecting people and ideas. Influenced by the thinking tools developed by Eli Goldgratt, the founders bring a unique approach to media in the life sciences. With help from our advisors around the industry, Mendelspod goes beyond quick sound bites to create a space for probing conversations and deep insight into the topics and trends which shape the industry's future and therefore our future as a species.
518 Available Episodes (518 Total)Average duration: 00:00:00
Apr 19, 2023
Elegen Pioneers Long DNA Subindustry with CEO Matt Hill
Unknown
Long DNA has arrived. Elegen, a new company based in San Carlos, California, is out this year offering just long DNA. According to their founder and CEO, Matt Hill and today's guest, the company’s product is twenty times more accurate than anything else presently available.
What does this mean for the world of biology and the world in general that we're seeing the emergence of a new subindustry devoted specifically to long DNA?
Mar 23, 2023
Nevermind the $200 Genome, Element CEO Molly He Says Core Chemistry Capable of Much More
Unknown
"We’re not a sequencing company," says Molly He, CEO and co-founder of Element Biosciences in our first interview with the leader of the hot new sequencing company which seemed to come out of nowhere this past year. “We’re a biology company.”
Not a sequencing company? Element has just taken the lead in the race toward cheap clinical genomes, and their CEO is putting that news aside in today’s interview. Instead, she’s much more interested in touting the company’s core technology “avidity.” The term comes from a core reagent the company has labeled an “avidite.”
Mar 16, 2023
3D Genomics Solves Cancer Case Where Sequencing Came Up Short: Anthony Schmitt, Arima Genomics
Unknown
Biology is complex, and the life science tool kit continues to expand to meet the challenge of that complexity taking us into the world of multi omics and beyond. Today we talk about 3D genomics and what this additional three-dimensional structural information is telling not just researchers, but clinicians, particularly in oncology.
Mar 08, 2023
New Spatial Company Maps Cell Surface Proteome without Imaging
Unknown
Today we talk with Simon Fredriksson, CEO and co-founder of Pixelgen Technologies, a company just out of stealth offering spatial technology that maps cellular surface proteins at the single cell level. Called molecular pixelation, the breakthrough technology is designed to first target immune cells.
Feb 23, 2023
John Greally on His Latest Review of Epigenomics
Unknown
Editor's Note: Theral's mic malfunctioned in this interview. Fortunately the not as good backup mic did work and John has a good mic. Our apologies.
John Greally joins us today. He is the founding Director of the Albert Einstein College of Medicine’s Center for Epigenomics. He’s a pediatrician and a clinical geneticist with appointments in both at Einstein.
Feb 15, 2023
President of ASHG on Eugenics Apology, Diversity Initiative
Unknown
Last month the American Society of Human Genetics (ASHG) took a quite remarkable step, putting out a formal statement of apology for its past history of involvement with eugenics. Some say it’s long overdue while some of us didn’t know about this history.
Feb 02, 2023
23andMe Launches New Personalized Healthcare Initiative with Amy Sturm
Unknown
23andMe occupies its own place in the world of genomics. Known for its vision to democratize human genomic information, the company has always gone big and bold, and sometimes controversial. Today we don’t hear much controversy—is that because their approach has won out? In any case, they have certainly achieved a scale that surpasses any other genetic testing company.
Jan 23, 2023
Converting Digital to Biological: John Gill, Telesis Bio
Unknown
Remember all those firsts for synthetic biology that we heard about coming from Craig Venter’s company, Synthetic Genomics in San Diego? The first genome of a whole organism transplanted. First genome synthesized. First synthetic life created.
Jan 17, 2023
50% Not Tested: Precision Oncology with Jerome Madison, Invitae
Unknown
Oncology has emerged as the most successful disease area for precision medicine. Last year, as the genetic testing industry went through a royal shake-up brought on mostly by external market forces, it's been no surprise that precision oncology has been touted as a core strength. As the industry now works "to be more lean and profitable"--new language one hears these days, cancer testing will be a big part of that effort.
Jan 05, 2023
Paul Freemont on Synthetic Biology in the UK
Unknown
To begin the year, we head across the pond for an outlook on the thriving community of synthetic biology in the United Kingdom.
Paul Freemont was a co-author of the UK's synthetic biology roadmap and co-directs SynbiCITE, the national center for the commercialization of synthetic biology. A few years ago the government put an initial investment of $300 million pounds into the field, and "everything was going swimmingly well," says Paul. "Then COVID happened."
Apr 19 | Unknown
Elegen Pioneers Long DNA Subindustry with CEO Matt Hill
Mar 23 | Unknown
Nevermind the $200 Genome, Element CEO Molly He Says Core Chemistry Capable of Much More
Mar 16 | Unknown
3D Genomics Solves Cancer Case Where Sequencing Came Up Short: Anthony Schmitt, Arima Genomics
Mar 08 | Unknown
New Spatial Company Maps Cell Surface Proteome without Imaging
Feb 23 | Unknown
John Greally on His Latest Review of Epigenomics
Feb 15 | Unknown
President of ASHG on Eugenics Apology, Diversity Initiative
Feb 02 | Unknown
23andMe Launches New Personalized Healthcare Initiative with Amy Sturm
Jan 23 | Unknown
Converting Digital to Biological: John Gill, Telesis Bio
Jan 17 | Unknown
50% Not Tested: Precision Oncology with Jerome Madison, Invitae
Jan 05 | Unknown
Paul Freemont on Synthetic Biology in the UK
This podcast could use a review!
This podcast could use a review! Have anything to say about it? Share your thoughts using the button below.